COPD and Asthma Devices Market

Market Overview:

The global COPD and asthma devices market size reached US$ 43.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 60.4 Billion by 2028, exhibiting a growth rate (CAGR) of 5.31% during 2023-2028.

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that leads to obstructed airflow from the lungs. Its early symptoms include shortness of breath, wheezing, chest tightness, chronic cough with or without mucus, frequent cold, and throat soreness. On the other hand, asthma, also known as bronchial asthma, is a respiratory disorder that affects the airways in the lungs. Its symptoms are shortness of breath, chest tightness, trouble sleeping, and coughing or wheezing attacks. These respiratory diseases are treated using various devices that help deliver inhaled medication. COPD and asthma devices, also known as pulmonary drug delivery devices, are used as permanent treatment or rescue therapy for respiratory diseases. As a result, they are gaining immense traction across the globe.

COPD and Asthma Devices Market Trends:

The growing global geriatric population, which is highly susceptible to chronic respiratory disorders, represents one of the key factors positively influencing the market. In addition, rising occurrences of respiratory diseases caused due to the rising smoking of cigarettes are increasing the sales of COPD and asthma devices. Apart from this, the increasing expenditure on healthcare and continuous automation in the healthcare industry are contributing to the market growth. The widespread adoption of advanced medical solutions is offering lucrative growth opportunities to manufacturers across the globe. At present, healthcare practitioners and pulmonary diseases specialists are preferring a combination of a drug and a device on account of their fast and effective outcome. Furthermore, the expansion of chemical industries is resulting in the rising environmental pollution level and breathing problems, which, in turn, is driving the market. Additionally, the introduction of portable drug delivery devices is propelling the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global COPD and asthma devices market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

• Inhalers
  • Drug Powdered Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers
• Nebulizers
  • Compressor Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers
     

Breakup by Indication:

• Asthma
• COPD
   

Breakup by Distribution Channel:

• Retail Pharmacies
• Hospitals
• Online Pharmacies
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Adherium Limited, Aristopharma Ltd., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, Cohero Health Inc., Koninklijke Philips N.V., Omron Corporation, Pari Respiratory Equipment Inc., Recipharm AB and Verona Pharma plc.

Report Coverage: